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ARTICLE

Alternative Splicing of the SLCO1B1 Gene: An Exploratory
Analysis of Isoform Diversity in Pediatric Liver
Bianca D. van Groen1, Chengpeng Bi2, Roger Gaedigk2, Vincent S. Staggs3, Dick Tibboel1, Saskia N. de Wildt1,4 and J. Steven Leeder2,*

The hepatic influx transporter OATP1B1 (SLCO1B1) plays an important role in the disposition of endogenous substrates and
drugs prescribed to children. Alternative splicing increases the diversity of protein products from > 90% of human genes and
may be triggered by developmental signals. As concentrations of several endogenous OATP1B1 substrates change during
growth and development, with this exploratory study we investigated age-dependent alternative splicing of SLCO1B1 mRNA
in 97 postmortem livers (fetus-adolescents). Twenty-seven splice variants were detected; 10 were confirmed by additional
bioinformatic analyses and verified by quantitative polymerase chain reaction, and selected for detailed analysis based on
relative abundance, association with age, and overlap with an adjacent gene. Two splice variants code for reference OATP1B1
protein, and eight code for truncated proteins. The expression of eight isoforms was associated with age. We conclude that
alternative splicing of SLCO1B1 occurs frequently in children; although the functional consequences remain unknown, the
data raise the possibility of a regulatory role for alternative splicing in mediating developmental changes in drug disposition.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ The hepatic influx transporter OATP1B1 (SLCO1B1)
transports substrates that include drugs that are prescribed to children, and endogenous substrates that are
involved in growth and development. Alternative splicing
may be triggered by developmental signals; no data regarding alternative splicing of SLCO1B1 are available.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Given that concentrations of several endogenous
OATP1B1 substrates change during growth and development, this study addressed the question of whether
SLCO1B1 undergoes alternative splicing and the potential
relationship with age.

Transporters are membrane-bound proteins that are present
in the apical and basolateral membranes of organs, such as
the liver.1 Their biological role is the trafficking of substrates
across membranes, making them critical determinants of
tissue and cellular substrate disposition. Moreover, they
act in concert with drug-metabolizing enzymes (DMEs) to
maintain homeostatic balance for endogenous substrates
and to facilitate the detoxification and elimination of exogenous substrates, such as drugs and food toxins.2
This latter is important for newborns, as after birth they
become dependent on exogenous food sources for nutrition, and the diet expands as they grow into infanthood.
1

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ Alternative splicing of SLCO1B1 occurred commonly in
pediatric liver tissue, and the expression of several splice
variants was associated with postnatal age. Most alternative transcripts were predicted to code for truncated
forms that may lack transporter activity.
HOW MIGHT THIS CHANGE CLINICAL PHARMA
COLOGY OR TRANSLATIONAL SCIENCE?
✔ Interpretation of these data raises the possibility of a regulatory role for alternative splicing in mediating developmental changes in drug disposition pathways during growth and
maturation and can stimulate further research to better understand age-related changes in the expression of OATP1B1.

During all these changes in food exposure, the child must
defend itself against potentially toxic dietary constituents,
recruiting pathways not or differentially expressed during
fetal life. Hence, ontogeny of DMEs and transporters occurs,
influencing the disposition of their endogenous and exogenous substrates over age. Moreover, ontogeny may well be
driven by developmental homeostatic changes in endogenous substrates.3
A classic example of age-related changes in a DME that
plays an important physiological role is hepatic cytochrome
P450 (CYP)3A7. CYP3A7 is highly expressed in fetal liver but
steadily declines throughout the last trimester of pregnancy
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and the first year of postnatal life to low levels characteristic
of an adult liver.4,5 From a functional perspective, CYP3A7
catalyzes the 16α-hydroxylation of dehydroepiandosterone
3-sulfate (DHEA-S), to form 16α-DHEA-S, a precursor for estriol synthesis by placental syncytiotrophoblasts.6 DHEA-S
concentrations are high during the fetal and neonatal periods and decline postnatally.7,8 DHEA-S has been reported
to activate CYP3A7 activity, which explains the high expression of CYP3A7 in the fetal liver.9 DHEA-S also provides an
example of the interplay between DMEs and transporters in
a developmental context, as prior to biotransformation by
CYP3A7 in fetal liver DHEA-S needs to cross the hepatocyte
membrane, using the solute carrier organic anion transporter
(gene name SLCO1B1, protein name OATP1B1) located
on the basolateral membrane.10 Consistent with CYP3A7,
the OATP1B1 expression also has been demonstrated to
decline directly after birth,11 followed by age-dependent
increases in mRNA expression throughout childhood.12
Data are conflicting regarding developmental patterns of
OATP1B1 protein, with expression increased around age
8 years, compared with younger children in one study, using
immunoblotting techniques,13 and no apparent statistically
significant relationship with age, using a quantitative proteomic approach.14
Whereas the contribution of CYP3A7 to drug clearance
postnatally is relatively minor, OATP1B1 plays an important role in the clearance of potentially toxic endogenous
molecules. One example illustrating the importance of
transporter function early after birth involves bilirubin; an
association has been demonstrated between the SLCO1B1
388G>A allele, a variant associated with reduced function
of the transporter, and unconjugated hyperbilirubinemia
in newborns, which is associated with neurotoxicity.15,16
Moreover, OATP1B1 is not only involved in the disposition
of endogenous substrates but also of drugs that are used
in pediatrics, such as statins, methotrexate and bosentan.10 Malfunctioning of the OATP1B1 transporter may put
children at risk of toxic or subtherapeutic effects of these
drugs. Thus, understanding the regulatory mechanisms of
the gene SLCO1B1 in response to developmental signals
is critical to understand physiological changes in endogenous substrates and to provide safe and effective drug
therapy in children.
To date, ontogeny studies have generally focused on
mRNA expression and, more recently, have expanded to
protein abundance targeting specific regions of the reference gene and/or protein sequence. Recently, it has become
increasingly apparent that alternative splicing, a process
that increases the diversity of products from a single gene,
may have functional consequences. Due to alternative
splicing events, > 90% of our genes give rise to more than
one mRNA transcript, varying with respect to numbers of
exons, different length of exons, and varying lengths of untranslated regions.17 Not all products of alternative splicing
necessarily result in the production of functional proteins.
Alternative splicing may be the result of developmental
signals expressed during the course of growth and development.17–19 For example, developmentally regulated
alternative splicing has been demonstrated for neuronal
sodium channels genes SCN1A, SCN2A, SCN3A, SCN8A,
Clinical and Translational Science

and SCN9A in brain tissue; the alternative exon 5N predominates in the neonatal period whereas 5A predominates in
the adult.20–25 In the case of SCN1A, a gene implicated in
the pathogenesis of febrile seizures in newborns,26 an allelic
variant SCN1A IVS5–91 G>A disrupts the 5’ splice donor
site of exon 5N and potentially influences the relative expression of exons 5N and 5A. Although the SCN1A IVS5–91
G>A variant does not seem to be associated with febrile
seizures per se,27 studies suggest that presence of the variant allele may affect dose requirements for phenytoin and
carbamazepine.25,28 Thus, alternative splicing and genetic
variants affecting alternative splicing may have therapeutic
consequences.
The SLCO1B1 gene, consisting of 14 coding and one
non-coding exons, codes for the protein OATP1B1 that
is composed of 691 amino acids, and consists of 12
transmembrane (TM) regions.10 It is part of the SLCO1B
family, for which splice variants have been described. For
example, five mRNA transcripts for SLCO1B3 have been
deposited in Ensembl, of which four represent full-length
or truncated protein-coding sequences.29 Furthermore,
the splice variant LST-3TM12 is a hybrid transcript with
sequences derived from SLCO1B3 and SLCO1B7, and
has functional transporter properties.30 In contrast, for
SLCO1B1, there is only one reported mRNA transcript,
ENST00000256958.2, encoding the functional 691 amino
acid OATP1B1 protein; referred to hereafter as the “reference isoform.”10
Given these considerations, the purpose of this exploratory study was to investigate alternative splicing of
SLCO1B1 in postmortem pediatric liver tissue over a wide
age range from fetal to adolescent ages. Using RNA sequencing (RNA-seq) data, we created a process involving
computational software integrating our bioinformatics pipelines and an in-house developed RNA-seq database query
system to perform a structured analysis of the RNA-seq data
in silico. Using this data analysis pipeline, we aimed (1) to
predict splice variants for SLCO1B1, (2) to identify potential
hybrid splice variants overlapping SLCO1B1 and SCLO1B7
(another member of the SLCO1B family), and (3) to study
age-related changes in expression of SLCO1B1 splice
variants.
MATERIALS AND METHODS
See Figure 1 for the workflow of the methods, and the explanation underneath.
Tissue samples
Postmortem liver tissue samples from autopsies of fetuses
(therapeutic abortions or stillbirths) and infants were provided by the Erasmus MC Tissue Bank (Rotterdam, The
Netherlands) and the repository of the Division of Clinical
Pharmacology, Toxicology, and Therapeutic Innovation at
Children’s Mercy Kansas City (Kansas City, MO). Tissue
was procured at the time of autopsy within 24 hours after
death and snap-frozen at −80°C for later research use.
For the tissues provided by the Erasmus MC Tissue Bank,
the Erasmus MC Research Ethics Board waived the need
for formal ethics approval according to the Dutch Law on
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Figure 1 Flow of methods predicting splice variants of SLCO1B1. NCBI, National Center for Biotechnology Information; ORF, open
reading frame; TM, transmembrane; TPM, transcripts per million.

Medical Research in Humans. Tissue was collected when
parental written informed consent for both autopsy and
the explicit use of the tissue for research was present.
The samples were selected when the clinical diagnosis
of the patient was not related to hepatic problems and
the tissue was histologically normal (as estimated by a
pathologist based on hematoxylin and eosin staining).
Postmortem pediatric liver tissues in the repository of
the Division of Clinical Pharmacology, Toxicology, and
Therapeutic Innovation at Children’s Mercy Kansas City
(Kansas City, MO) were obtained from multiple sources,
including the Brain and Tissue Bank for Developmental
Disorders at the University of Maryland (Baltimore, MD),
the Liver Tissue Cell Distribution System (University of
Pittsburgh, and University of Minnesota), University of
Washington Center for Birth Defects Research (Seattle,
WA), and XenoTech LLC (Lenexa, KS). The use of these

tissues was declared nonhuman subject research by the
Children’s Mercy Hospital Pediatric Institutional Review
Board.
RNA-seq
The mRNA expression of SLCO1B1 was determined using
RNA-seq. RNA was isolated from hepatic tissue according to the manufacturer’s instructions using the RNeasy
Mini kit (Qiagen, Valencia, CA). Samples with an RNA
integrity number of < 5 were excluded. The RNA-seq
experiments were performed according to the Illumina
RNA-seq protocol (San Diego, CA). In brief, a population of poly(A)+ mRNA was selected and converted to a
library of cDNA fragments (220–450 bp) with adaptors
attached to both ends, using an Illumina mRNA-Seq
sample preparation kit. The quality of the library preparation was confirmed by analysis on a 2100 Bioanalyzer
www.cts-journal.com
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(Agilent Technologies, Santa Clara, CA). The cDNA fragments were then sequenced on an Illumina HiSeq 2000
to obtain 100-bp sequences from both ends (paired
end). The resulting reads were mapped by Bowtie2 and
StringTie 31–33 to the transcriptome constructed through
reference genes/transcripts, according to the reference
human genome GRCh37.61/hg19.34 The mapped reads
were then assigned to transcripts from which the abundance of the reference transcript is estimated by RSEM35
and for the splice variants with HISAT2.36 The counts of
RNA-seq fragments were used to indicate the amount of
identified mRNA transcripts, presented in transcripts per
million (TPM).35
Validation data set
To validate the RNA-seq results, the presence of the reference transcript was confirmed (Ensembl transcript ID
ENST00000256958.3). Moreover, to further validate the
results, the presence of the alternatively spliced transcript
LST-3TM1230 was detected using the algorithm RSEM
combined with Bowtie2 and the assembly GRCh37.
Protein prediction
Sequence alignment and overlap of splice variants with
consensus coding sequences37 for SLCO1B1 and the adjacent gene SLCO1B7 was performed using Basic Local
Alignment Search Tool (BLAST).38 Splice variants were prioritized for further investigation when one of the following
criteria was met and when the presence of the splice variant
was verified with real-time polymerase chain reaction (RTPCR; see section Verification of splice variants by RT-PCR
and sequencing):
• The expression of the splice variant was > 5% of the expression of the reference isoform,
• The splice variant was a SLCO1B7 and SLCO1B1 hybrid
transcript, or
• The expression of the splice variant was associated with
age (see section Data and statistical analysis for statistical analysis).
Next, the open reading frame (ORF) of > 600 nucleotides
(nts) of the relevant splice variants was predicted with ORFFinder by the National Center for Biotechnology Information.39
Prediction of TM regions and orientation was done with
TMpred based on the TMbase database.40 Two-dimensional
protein structures were generated with TOPO2.41
To provide additional bioinformatic confirmation that
candidate novel alternatively spliced products represent
coding transcripts, sequencing data were analyzed using
two additional tools: the Coding Potential Calculator
Algorithm (CPC2) and the Coding-Potential Assessment
Tool (CPAT).42,43 These algorithms both use logistic regression to distinguish between coding and noncoding
transcripts based on four intrinsic features: the Fickett testcode score (both), ORF length (both), ORF integrity (CPC2),
isoelectric point (CPC2), ORF coverage defined as the ratio
of ORF to transcript lengths (CPAT), and hexamer usage
bias (CPAT).
Clinical and Translational Science

Verification of splice variants by RT-PCR and
sequencing
The presence of the splice variants selected for further
investigation was verified by RT-PCR and sequencing.
Primers were designed to be specific for each splice variant
(Figure S1 and Table S1). In addition, a universal primer pair
was designed to amplify all splice variants and to function
as a positive control. Due to the low abundance of some of
the variants, a nested forward primer was also designed.
RNA was extracted from frozen liver tissue, utilizing the
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA). One µg of
total RNA was DNase treated and reverse transcribed with
the Maxima H Minus First Strand cDNA Synthesis Kit, following the manufacturer’s instructions (Thermo Scientific,
Waltham, MA). The cDNA equivalent to 10 ng of total RNA
was used per polymerase chain reaction (PCR; 2G Fast
ReadyMix, KAPA Biosystems, Wilmington, MA). The cycling
conditions were: 94°C, 3 minutes, followed by 40 cycles
of 94°C for 15 seconds, 60°C for 15 seconds, and 72°C
for 5 seconds. The primary PCR amplicons were diluted
1:4,000 and a nested PCR was performed with the same
KAPA mix and the same cycling conditions. The PCRs were
column purified up with the QIAquick PCR Purification Kit
(Qiagen). One ng was used in subsequent sequencing reactions with BigDye version 3.1 and run on a 3,730xl DNA
Analyzer (Thermo Scientific). The results were analyzed with
Sequencher software (Gene Codes, Ann Arbor, MI).
Data and statistical analysis
Because of non-normal distribution, the data are presented
as median (range). First, the relative abundance of the expression of each transcript compared with the reference
isoform was calculated. In addition, the relationship of age
with expression levels (TPM) was studied by comparing
expression levels between age groups. Samples were assigned to one of five age groups: fetal, 0–1.5, 1.5–6, 6–12,
and 12–18 years. KruskalWallis test with Dunn’s post hoc
test were used for multiple comparisons of expression
levels between age groups. For Dunn’s post hoc test for
multiple comparisons, the adjusted P values are reported,
in which a correction for multiple testing for age groups is
applied. Second, Spearman correlations between age (on
a continuous scale) and expression levels of splice variants
were examined. To control for the number of correlations
tested (54), P values were considered statistically significant only if their corresponding q value was < .05 after
BenjaminiHochberg adjustment to control the false discovery rate. Statistical analyses were performed using IBM
SPSS Statistics software (SPSS Statistics for Windows,
version 21.0; IBM, Armonk, NY) and graphical exploration
was done with GraphPad Prism. We explored negative binomial and zero-inflated negative binomial models in SAS
9.4, but the former did not fit well, and we were unable to
identify predictors of excess zeros for the latter.
RESULTS
Descriptive results
The mRNA expression of the reference isoform and splice
variants of SLCO1B1 was quantified in 97 postmortem
liver tissues of humans of various ages, of which the age
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distribution can be found in Table 1. The reference isoform of
SLCO1B1 was detected in all but one sample with a median
expression of 33.4 (range 0–134.2) TPM. The transcript consisted of 2,791 nts of which 95 nts comprise the 5’-UTR and
621 nts the ’3-UTR, resulting in a protein of 691 amino acids.
This is in accordance with Niemi et al.10 In Figure 2a the expression of this transcript in various age groups is presented
and did not show any age-related changes when binned in
age groups. On the other hand, on a continuous scale, postnatal age was related to transcript expression (ρ = 0.316,
P = 0.002; Figure 2d). Twenty-seven splice variants of
SLCO1B1 were identified using RNA-seq, representing a
total expression of 18.8 (0.2–105.0) TPM (Figure 2b). These
are numbered randomly between 21 and 55. The ratio of the
Table 1 Median (range) age by group for postmortem liver samples

Age groups

Number of samples

Gestational
age (weeks)

Postnatal
age (years)

Fetus

22

16.4 (14.7–41.3)

–

0–1.5 years

35

–

0.1 (0–1.2)

1.5–6 years

16

–

3 (1.8–6)

6–12 years

15

–

9 (7–12)

12–18 years

9

–

15 (13–17)

Total

97

total expression of the splice variants vs. the reference isoform is presented in Figure 2c and was not different between
age groups. Thirteen splice variants met the selection criteria
for further analysis, and 10 of these were subsequently verified by RT-PCR (Table 2), as described below.
Verification of splice variants by RT-PCR and
sequencing
The presence of the splice variants meeting one or
more criteria of (i) expression level > 5% of the expression of the reference isoform, (ii) a hybrid SLCO1B7 and
SLCO1B1 transcript, or (iii) expression was associated
with age, were verified for 10 of 13 samples; splice variants 21, 37, and 48 could not be verified by RT-PCR (see
Figure S2). Splice variants 21 and 37 had sizes different
than expected. Splice variant 48 could not be amplified.
Further analysis of variants 21, 37, and 48 by sequencing
was also unable to confirm the presence of the 21, 37,
and 48 splice variants, and, thus, these transcripts were
excluded from further analysis. The splice junctions of
variant 46 were not sufficiently unique to design primers
that would amplify only this variant or to generate a product with a size that could be resolved on an agarose gel
from amplicons generated from other transcripts as templates. The results for splice variant 46 should, therefore,
be interpreted with caution.

Figure 2 Transcripts per million (TPM) expression of (a) the reference isoform of SLCO1B1 (b) the total TPM values of splice variants
and (c) the ratio of total TPM values of splice variants to TPM values of the reference isoform in various age groups; and (d) the
relationship of the reference isoform of SLCO1B1 with postnatal age (ρ = 0.316, P = 0.002).
www.cts-journal.com
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–

Splice variants meeting the abundance criterion
Three splice variants had an abundance of > 5% of the
expression of the reference isoform (Table 2). They had
40–90% overlap with the ORF from the reference amino
acid sequence for OATP1B1, resulting in a prediction of a
number of TM helices ranging from 6 to 11. These three
splice variants are, therefore, predicted to result in truncated versions of OATP1B1.

–

–

1.21

0.34

0.52

7.86

0.73

26c,d

28c,d

30 c,d

38d

44d

51d

AA, amino acid; nt, nucleotides; ORF, open reading frame; RT-PCR, real-time polymerase chain reaction; TM, transmembrane.
a
SLCO1A2 is on the reverse strand. bAbundant splice variant. cHybrid SLCO1B1 and -1B7. dAge-related changes in expression.

2

Validation data set
To further validate our RNA-seq results, we confirmed the
presence of the LST-3TM12 transcript30 in our samples.
The transcript emerged in 3 of the 97 samples with a low
abundance of 0.11, 0.18, and 0.30 TPM.

–

–
98 (14%)

522 (75%)

98

15,407

1.80

24c,d

3

76
0.46

9.24

0.32

34b

17

65
4.88

7,364

522

–

–

8

10
–
9
444 (65%)
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15
95
0.33

22,310

453

–

–

1

31
54
0.21

20

5,684

–
453 (66%)
484

0

–

0

881
–
–
881

–

–

12
–

210

–

–

–

–

–
210

14,577
20
96
0.75

–

691 (100%)
691

0

11

12
–
–
81
1.12

24

13,158

–
691 (100%)
691

0

–

11
–

37

3
–

622 (90%)

–

–
622 (90%)
625

3,151

18

77

25

46
5.73

0.20

4,156

659

0

6

10

–

–

–

–
9

–
10
274 (40%)

444 (65%)

284
4,638

17
93

10
63

14.26

8.85

26.55

50b

Splice
variant

46b,d

16.48

34,388

453

–

SLCO-1A2a
Number of
exons

Length (nt)

ORF (n AA)

Intron
SLCO1B1

ORF
SLCO1B7

In between
SLCO1B1
and
SLCO1A2a
ORF SLCO1B1
(% of reference
SLCO1B1)
Found in
number of
samples
Abundance
compared with
reference
isoform (%)
Abundance
of all novel
isoforms (%)

Overlapping number of AA with locus:

Table 2 Relevant splice variants of SLCO1B1 in 97 pediatric liver samples for which the presence in the samples is confirmed by RT-PCR

Number of
TM helices
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Splice variants overlapping with SLCO1B7 and
SLCO1B1
Four splice variants were identified with exons overlapping
the SLCO1B1 as well as the SLCO1B7 gene region (Table 2).
They all had an ORF overlapping > 40% of the amino acid
sequence of OATP1B1. However, the ORF of none of them
was overlapping the SLCO1B7 region. Two of these isoforms are predicted to translate into similar protein versions
of OATP1B1, as they have 100% overlap with the reference
isoform. All four splice variants have longer untranslated regions than the reference isoform.
One isoform, sv28, overlapped with SLCO1A2. This
hybrid isoform contains an intron-less complete coding sequence, which is officially located in intron 13 of
SLCO1A2.
Splice variants with age-related expression
Age groups. The splice variants 26 and 46 showed agerelated changes in their expression with lower expression
in fetal tissue than in tissue from older children (see
Figure 3a for specific changes and Table 2 for splice
variant information). When analyzed as a ratio to the
expression of the reference isoform, for one splice variant
(26) the ratio variant/reference isoform increased with
age, whereas three splice variants decreased with age:
isoforms 24, 28, and 44 (see Figure 3b for specific
changes and Table 2 for splice variant information). This
latter observation reflects that for the individual samples
either the expression of the splice variant was lower,
or the expression of reference isoform was higher. As
the expression of the reference isoform was shown to
be similar when binned in age groups (Figure 3a), it is,
therefore, likely that the expression of the splice variants
that decreased with age was lower.
Age on continuous scale. The expression of four of the five
hybrid SLCO1B7 and SLCO1B1 splice variants (24, 26, 28,
and 30) and the abundant splice variant 46 are significantly
correlated with age (see Table 3). More specifically, the
expression of the splice variants 24 and 28 decreased
with increasing age, and the expression of 26, 30, and
46 increased with increasing age. When splice variant
expression is analyzed as a ratio to the expression of the
reference isoform, correlation with age was found for the
same and for four additional splice variants (see Table 3).
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Figure 3 Expression (a) and expression in relation to the reference isoform (b) of developmentally regulated splice variants of SLCO1B1
in various age groups. Counts of tissues with isoform expressed out of total counts by age group are provided in parentheses.
*P < 0.05; **P < 0.01. TPM, transcripts per million.
www.cts-journal.com
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Table 3 Spearman correlations expression splice variant vs.
postnatal age

Expression splice
variant (TPM) vs.
postnatal age
(weeks)
Splice variant

rs

P value

Ratio expression
splice variant/
reference isoform
vs. postnatal age
(weeks)
rs

P value

21

0.231

0.023

0.194

0.057

24

−0.330

0.001*

–0.392

0.000*

26

0.489

0.000*

0.518

0.000*

28

–0.263

0.009*

–0.433

0.000*

30

0.290

0.004*

0.296

0.003*

33

0.142

0.166

0.143

0.163

34

0.133

0.193

0.110

0.285
0.029

35

–0.035

0.734

–0.222

36

0.063

0.539

0.058

0.575

37

0.069

0.501

0.006

0.955

38

–0.070

0.496

–0.271

0.007*

39

–0.141

0.167

–0.188

0.065

40

–0.017

0.869

–0.092

0.371

41

0.003

0.977

–0.001

0.990

42

0.055

0.591

–0.059

0.566

43

0.065

0.528

0.063

0.542

44

–0.121

0.240

–0.259

0.010*

45

–0.017

0.867

–0.020

0.843

46

0.386

0.000*

0.343

0.001*

47

–0.023

0.825

–0.106

0.299

48a

–0.243

0.016

–0.463

0.000*

49

–0.117

0.253

–0.146

0.152

50

0.204

0.045

–0.202

0.047
0.002*

51

–0.177

0.083

–0.308

53

–0.029

0.779

–0.043

0.678

54

–0.155

0.129

–0.169

0.097

55

–0.173

0.091

–0.203

0.046

TPM, transcripts per million.
a
Excluded from further analysis because the presence was not confirmed
by real-time polymerase chain reaction (RT-PCR; see section Verification
splice variants by RT-PCR and sequencing).
Bold and * indicate significant after adjustment to control false discovery
rate at 0.05.

The expression of splice variant 48 was correlated with
age, but was excluded for further analysis as their presence
was not verified by RT-PCR (see section Verification splice
variants by RT-PCR and sequencing).
Predicted protein structure
In Table S3, the coding-potential prediction results using
the CPAT and CPC2 tool are depicted. Splice variant 44
has a low coding probability, hence will likely not result in
a protein product. This can be explained by the fact that
the ORF length was small compared with the size of the
splice variant or because of a high hexamer-score.42,43
The hexamer-score is a feature dependent on adjacent
amino acids in proteins and is based on a log-likelihood
ratio to measure differential hexamer usage between coding and noncoding sequences.44 All other splice variants
Clinical and Translational Science

have a very high probability to be translated into a protein
product. In Figure 4a, the 2D structure of OATP1B1 is
presented, consisting of 12 TM helices. In Figure 4b, the
predicted 2D structure of the splice variants with an ORF
with high probability to be translated in a protein product
are presented.
DISCUSSION
In the current study, we have developed a data analysis pipeline that allowed a structured analysis of a large amount of
RNA-seq data generated from pediatric liver samples and
used this to investigate alternative splicing of the SLCO1B1
gene that could potentially translate into functional OATP1B1
proteins. More specifically, we report three major findings
from the 10 relevant splice variants that we identified: (i) 2
splice variants are predicted to translate into the same amino
acid sequence as the reference isoform for OATP1B1; (ii)
8-splice variants may translate into truncated versions of the
OATP1B1 protein because of an altered length of amino acid
sequence, and (iii) the expression of 8 splice variants was associated with age. None of the splice variants had an ORF
that covered the SLCO1B7 region.
Our results show that the SLCO1B1 gene locus is subject to alternative splicing, as supported by the major
findings presented above. More specifically, the fact that
eight splice variants of SLCO1B1 showed a developmental pattern is consistent with developmentally regulated
alternative splicing as a mechanism for altered SLCO1B1/
OATP1B1 expression during growth and maturation. This
finding may have implications for the functionality of the
transporter in children, and with that the disposition of
its endogenous and exogenous substrates, as most of
these splice variants were predicted to result in truncated
OATP1B1 isoforms with fewer TM regions compared
with the reference OATP1B1 protein. Available evidence
suggests that SLCO1B7 is a pseudogene resulting in a
nonfunctional protein product with only 11 TM regions,
whereas the SLCO1B1 gene, the SLCO1B3 gene, and
the hybrid transcript LST-3TM12 give rise to at least one
mRNA transcript that translates into functional transporters with 12 TM regions.30 Moreover, the truncated proteins
encoded by the transcripts we observed may lack one
or more of the N-glycosylation sites Asn134, Asn503,
and Asn516, located at the extracellular loops 2 and 5 of
OATP1B1.45 Glycosylation is a post-translational modification that is suggested to be essential for the proper
function of OATP1B1. Disruption of all these sites led to
lower protein stability with reduced total protein levels,
and nonglycosylated OATP1B1 was retained within the
endoplasmic reticulum (e.g., it was not present on the cell
membrane).45
Some of the alternative proteins of OATP1B1 reported in
this study, therefore, are likely to result in nonfunctional protein
products incapable of cellular transport, but could possibly
possess alternative functional properties, such as regulating
the activity of the functional OATP1B1 transporter protein.
A precedent for this type of regulatory role is illustrated by
the DME UGT1A, a complex gene with three major mRNA
variants created by splicing events involving an alternative 5a
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Figure 4 (a) Predicted 2D structure of reference OATP1B1 (1: extracellular, 2: transmembrane, 3: intracellular) and (b) the predicted 2D
structure of splice variants of OATP1B1, centered on the fourth intracellular loop (dashed line) of the reference structure for OATP1B1.
The number of the splice variant is presented in the upper left corner of each structure. Red and blue: overlapping amino acid
sequence with OATP1B1. Blue: overlapping structure OATP1B1.

or 5b exon. The classic variant (i1) with exon 5a has transferase activity, whereas the alternative proteins (i2), with either
exon 5b or with both exon 5a and 5b, lack transferase activity.46 The relative glucuronidation of SN-38, a substrate for
UGT1A, was decreased in the presence of i2 proteins despite the same amount of i1 enzyme.47 This phenomenon is
explained by oligomerization of UGT1A enzyme; i2 proteins
can form dimers with i1 enzymes, inhibiting the activity of
i1 enzymes.48 Interestingly, OATP1B transporters not only
form homo-oligomers, but can also form hetero-oligomers,
even with transporters from another family (e.g., with
Na+/taurocholate co-transporting polypeptide (NTCP)).49,50
It has been demonstrated that a nonfunctional unit of
OATP1B3, containing a lysine at position 41 in place of the

wild-type cysteine in the homodimer, did not affect normal
substrate transport by the functional, cysteine-containing
OATP1B3 component of the homodimer, suggesting that
each unit within the dimer works as an independent functional unit.49 However, each splice variant may have its own
function and so we hypothesize that those resulting in truncated proteins may influence the transporter activity of the
reference protein OATP1B1 and other transporters.
The specific SLCO1B1 region is part of the wider SLCO1Bfamily region, which gives rise to the SLCO1B3/SLCO1B7
hybrid transcript LST-3TM12 that result in a functional transporter.30 The four SLCO1B1 splice variants found in this
study that contained exons covering the region of SLCO1B7
did not contain the start codon from the SLCO1B7 locus,
www.cts-journal.com
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thus we conclude that the SLCO1B1 gene is not subject to
hybridization with adjacent genes. However, the length of
the untranslated region (UTR) of these and other transcripts
could well be influencing the function of the transporter,
even when the ORF of the splice variant is the same as the
reference sequence. We note that a transcript of CYP3A4
with a shorter 3’-UTR than the canonical transcript due to
an additional polyadenylation site was more stable and generated more protein51 than an alternative transcript with a
longer 3’-UTR. Interestingly, this shorter transcript showed
developmental regulation as it was higher expressed in adult
livers than in pediatric livers. Nevertheless, it remains to be
seen whether this is also the case for the splice variants presented in this study.
Another consequence of these truncated versions of
OATP1B1 is that they may interfere with the estimation of
OATP1B1 content using liquid chromatography-
tandem
mass spectrometry-based proteomic methods. This
quantitative proteomic approach utilizes short peptides
to target the protein of interest. All truncated versions of
OATP1B1 presented in this paper contained the amino acid
sequences NVTGFFQSFK14 and of LNTVGIAK11 that have
been used in studies presenting results on expression of
OATP1B1 protein in pediatric liver tissue. The latter refers
to our previous study, where a poor correlation was seen
between total mRNA expression of SLCO1B1 as measured
with RNA-seq and protein abundance of OATP1B1 in a subset of the samples presented in the current study.11 This
lack of correlation can be explained by the fact that not all
mRNA transcripts translate into protein. Moreover, potential translation of splice variants into nonfunctional proteins
that are nevertheless detected by the peptide sequences
used to quantitate OATP1B1 content could also result in
poor correlations between abundance and activity. Thus,
care may be needed when extrapolating mRNA expression
to protein abundance, protein abundance to actual activity,
and ultimately the prediction of disposition of transporter
substrates.
We recognize that a limitation of our study is that our results are based on in silico predictions, and the presence
of the corresponding truncated proteins must be confirmed
by protein abundance studies before any of the implications
we propose above can be assessed, including investigations of a dominant-negative regulatory role analogous to
the UGT1A situation. Developmental regulation of alternative splicing is a commonly recognized phenomenon
during tissue development and cell differentiation. In fact,
level of expression, localization within the cell, mRNA stability, translation efficiency, and splicing of specific RNA
binding proteins (RBPs) is finely regulated. RBPs bind to cis-
elements and promote or inhibit splice site recognition, and,
therefore, RBP expression coordinates alternative splicing
networks during development.18 Further work is necessary
to characterize the specific developmental signals responsible for the observed changes in expression of the SLCO1B1
splice variants.
These exploratory data imply that the complexity of processes involved with growth and development throughout
childhood may have influences on transporter expression
and subsequent substrate disposition, as yet unrecognized.
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The observed age-related changes in expression of splice
variants in the context of age-related changes in concentrations of endogenous OATP1B1 substrates, such as DHEA-S
and 16alpha-hydroxylated metabolites, makes it tempting to
speculate that additional regulatory mechanisms may be in
play, with implications for the disposition of exogenous substrates used in pediatrics. Most importantly, the data analysis
pipeline we have developed allows the analyses described
in this paper for SLCO1B1 to be applied to any other gene
of interest and will be repeated for other transporters and
genes involved in drug disposition or growth of children in
the future.
In conclusion, we have shown that SLCO1B1 splice
variants with an ORF could potentially translate into proteins with unknown function; they are unlikely to code for
functional transporters but may have other roles, such as
regulatory activity. Moreover, as the expression of particular
SLCO1B1 splice variants showed age-related changes, the
data raise the possibility of a regulatory role for alternative
splicing in mediating developmental changes of SLCO1B1/
OATP1B1 in drug disposition. These data can contribute
to improved understanding of age-related changes in expression of SLCO1B1, and possibly other enzymes and
transporters involved in the disposition of endogenous and
exogenous substrates throughout growth and development.
Supporting Information. Supplementary information accompanies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
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